Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.69 |
| ▸ | PPARA | Q07869 | 3/20 | 0.64 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.64 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | SYK | P43405 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | NOX4 | Q9NPH5 | 2/20 | 0.56 |
| ▸ | EGFR | P00533 | 2/20 | 0.56 |
| ▸ | RGS12 | O14924 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29391099 | 1.00 | KDM4C (0.69) | KDM4CPPARASTING1FFAR1HIF1A | |
| SCHEMBL1250220 | 0.92 | KDM4C (0.58) | KDM4CPPARASTING1FFAR1HIF1A | |
| SCHEMBL15668518 | 0.89 | EGFR (0.67) | KDM4CPPARASTING1FFAR1HIF1A | |
| SCHEMBL609252 | 0.87 | SYK (0.60) | KDM4CPPARASTING1FFAR1SYK | |
| SCHEMBL29532272 | 0.83 | KDM4C (0.76) | KDM4CPPARASTING1SYKMAPT | |
| SCHEMBL611490 | 0.83 | KDM4C (0.76) | KDM4CPPARASTING1SYKMAPT | |
| SCHEMBL4823681 | 0.82 | CA1 (0.62) | KDM4CHIF1ASYKMAPTNOX4 | |
| SCHEMBL1250291 | 0.82 | FFAR1 (0.53) | KDM4CPPARAFFAR1HIF1AMAPT | |
| SCHEMBL607997 | 0.82 | KDM4C (0.74) | KDM4CPPARASTING1FFAR1SYK | |
| SCHEMBL609562 | 0.82 | PPARA (0.92) | KDM4CPPARASTING1SYKMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3902536-B1 | COMPOSITIONS COMPRISING 5-BENZYLAMINOSALICYLIC ACID COMPOUNDS FOR USE IN TREATING NEURODEGENERATIVE DISORDERS IN A COMPANION ANIMAL | GNT PHARMA CO LTD (KR) | 2025-09-03 | — | — | EP | claimed |
| WO-2023156808-A2 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS | GNT PHARMA CO., LTD. (KR) | 2023-08-24 | — | — | WO | claimed |
| US-20230233503-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS | GNT PHARMA CO., LTD. (KR) | 2023-07-27 | — | — | US | claimed |
| US-20220249343-A1 | COSMETIC COMPOSITION INCLUDING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE, AND TOPICAL USE THEREOF | GNT PHARMA CO., LTD. (KR) | 2022-08-11 | — | — | US | claimed |
| US-20220241231-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | GNT PHARMA CO., LTD. (KR) | 2022-08-04 | — | — | US | claimed |
| EP-3998058-A1 | COSMETIC COMPOSITION COMPRISING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE AND LOCAL ADMINISTRATION METHOD THEREOF | GNT Pharma Co., Ltd (KR) | 2022-05-18 | — | — | EP | claimed |
| EP-3902536-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | GNT Pharma Co., Ltd (KR) | 2021-11-03 | — | — | EP | claimed |
| WO-2021006637-A1 | COSMETIC COMPOSITION COMPRISING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE AND LOCAL ADMINISTRATION METHOD THEREOF | 주식회사 지엔티파마 | 2021-01-14 | — | — | WO | claimed |
| WO-2020136441-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | GNT PHARMA CO., LTD. (KR) | 2020-07-02 | — | — | WO | claimed |
| US-20200206172-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | GNT PHARMA CO., LTD. (KR) | 2020-07-02 | — | — | US | claimed |
| US-20120301551-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2012-11-29 | — | — | US | claimed |
| US-20120040939-A1 | MEDICINAL USE OF 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE OR ITS SALT | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2012-02-16 | — | — | US | claimed |
| US-20070298129-A1 | Compounds and compositions for treating neuronal death or neurological dysfunction | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2007-12-27 | — | — | US | claimed |
| US-20070049565-A1 | Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2007-03-01 | — | — | US | claimed |
| US-6964982-B2 | Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system | NEUROTECH CO., LTD. (KR) | 2005-11-15 | — | — | US | claimed |
| EP-1274675-B1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING NEURODEGENERATION IN ACUTE AND CHRONIC INJURIES IN THE CENTRAL NERVOUS SYSTEM | NEUROTECH CO LTD (KR) | 2004-09-01 | — | — | EP | claimed |
| US-20030045575-A1 | Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system | NEUROTECH CO., LTD. | 2003-03-06 | — | — | US | claimed |
| EP-1274675-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING NEURODEGENERATION IN ACUTE AND CHRONIC INJURIES IN THE CENTRAL NERVOUS SYSTEM | Neurotech Co., Ltd. (KR) | 2003-01-15 | — | — | EP | claimed |
| WO-2001079153-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING NEURODEGENERATION IN ACUTE AND CHRONIC INJURIES IN THE CENTRAL NERVOUS SYSTEM | NEUROTECH CO., LTD. (KR) | 2001-10-25 | — | — | WO | claimed |
| EP-3902536-B1 | COMPOSITIONS COMPRISING 5-BENZYLAMINOSALICYLIC ACID COMPOUNDS FOR USE IN TREATING NEURODEGENERATIVE DISORDERS IN A COMPANION ANIMAL | GNT PHARMA CO LTD (KR) | 2025-09-03 | — | — | EP | disclosed |
| US-20250255844-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS | GNT PHARMA CO., LTD. (KR) | 2025-08-14 | — | — | US | disclosed |
| US-12285402-B2 | Compositions and methods for treating pulmonary disorders | GNT PHARMA CO., LTD. (KR) | 2025-04-29 | — | — | US | disclosed |
| EP-4456890-A2 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS | GNT Pharma Co., Ltd (KR) | 2024-11-06 | — | — | EP | disclosed |
| WO-2023156808-A2 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS | GNT PHARMA CO., LTD. (KR) | 2023-08-24 | — | — | WO | disclosed |
| US-20230233503-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS | GNT PHARMA CO., LTD. (KR) | 2023-07-27 | — | — | US | disclosed |
| US-20220249343-A1 | COSMETIC COMPOSITION INCLUDING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE, AND TOPICAL USE THEREOF | GNT PHARMA CO., LTD. (KR) | 2022-08-11 | — | — | US | disclosed |
| US-20220241231-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | GNT PHARMA CO., LTD. (KR) | 2022-08-04 | — | — | US | disclosed |
| EP-3998058-A1 | COSMETIC COMPOSITION COMPRISING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE AND LOCAL ADMINISTRATION METHOD THEREOF | GNT Pharma Co., Ltd (KR) | 2022-05-18 | — | — | EP | disclosed |
| EP-3902536-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | GNT Pharma Co., Ltd (KR) | 2021-11-03 | — | — | EP | disclosed |
| WO-2021006637-A1 | COSMETIC COMPOSITION COMPRISING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE AND LOCAL ADMINISTRATION METHOD THEREOF | 주식회사 지엔티파마 | 2021-01-14 | — | — | WO | disclosed |
| US-20200206172-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | GNT PHARMA CO., LTD. (KR) | 2020-07-02 | — | — | US | disclosed |
| WO-2020136441-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | GNT PHARMA CO., LTD. (KR) | 2020-07-02 | — | — | WO | disclosed |
| EP-2394645-B1 | Medical use of 5-benzylamino salicylic acid derivatives or salts thereof | NEUROTECH PHARMACEUTICALS CO LTD (KR) | 2014-10-08 | — | — | EP | disclosed |
| US-20120301551-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2012-11-29 | — | — | US | disclosed |
| US-8211878-B2 | Method for reducing neuronal death in nervous system injuries resulting from amyotrophic lateral sclerosis | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2012-07-03 | — | — | US | disclosed |
| US-8211877-B2 | Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2012-07-03 | — | — | US | disclosed |
| US-20120040939-A1 | MEDICINAL USE OF 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE OR ITS SALT | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2012-02-16 | — | — | US | disclosed |
| US-20100331284-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING NEURODEGENERATION IN ACUTE AND CHRONIC INJURIES IN THE CENTRAL NERVOUS SYSTEM | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2010-12-30 | — | — | US | disclosed |
| US-20100323995-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING NEURODEGENERATION IN ACUTE AND CHRONIC INJURIES IN THE CENTRAL NERVOUS SYSTEM | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2010-12-23 | — | — | US | disclosed |
| US-7750045-B2 | Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2010-07-06 | — | — | US | disclosed |
| US-20090149542-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2009-06-11 | — | — | US | disclosed |
| US-20070298129-A1 | Compounds and compositions for treating neuronal death or neurological dysfunction | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2007-12-27 | — | — | US | disclosed |
| US-20070049565-A1 | Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2007-03-01 | — | — | US | disclosed |
| US-20060128677-A1 | Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system | NEUROTECH CO., LTD. | 2006-06-15 | — | — | US | disclosed |
| US-6964982-B2 | Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system | NEUROTECH CO., LTD. (KR) | 2005-11-15 | — | — | US | disclosed |
| EP-1274675-B1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING NEURODEGENERATION IN ACUTE AND CHRONIC INJURIES IN THE CENTRAL NERVOUS SYSTEM | NEUROTECH CO LTD (KR) | 2004-09-01 | — | — | EP | disclosed |
| US-6573402-B1 | 5-benzylamino salicylic acid and its derivatives as neuroprotective agents | NEUROTECH CO., LTD. (KR) | 2003-06-03 | — | — | US | disclosed |
| US-20030097018-A1 | Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system | NEUROTECH CO., LTD. | 2003-05-22 | — | — | US | disclosed |
| US-20030045575-A1 | Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system | NEUROTECH CO., LTD. | 2003-03-06 | — | — | US | disclosed |
| EP-1274675-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING NEURODEGENERATION IN ACUTE AND CHRONIC INJURIES IN THE CENTRAL NERVOUS SYSTEM | Neurotech Co., Ltd. (KR) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001079153-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING NEURODEGENERATION IN ACUTE AND CHRONIC INJURIES IN THE CENTRAL NERVOUS SYSTEM | NEUROTECH CO., LTD. (KR) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001079153-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING NEURODEGENERATION IN ACUTE AND CHRONIC INJURIES IN THE CENTRAL NERVOUS SYSTEM | NEUROTECH CO., LTD. (KR) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149542-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION | BCL2, BAX, SMN1; SMN2 | KDM4C 3544/4885PPARA 1265/4885STING1 3945/4885 |
| US-20120301551-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION | BCL2, BAX, SMN1; SMN2 | KDM4C 3544/4885PPARA 1265/4885STING1 3945/4885 |
| US-20230233503-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS | HAO2, ACOX1, HAO1 | KDM4C 3145/4885PPARA 813/4885STING1 2942/4885 |
| US-20220241231-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | PRNP, PSEN1, GRIK5 | KDM4C 2280/4885PPARA 3388/4885STING1 3242/4885 |
| US-20100331284-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING NEURODEGENERATION IN ACUTE AND CHRONIC INJURIES IN THE CENTRAL NERVOUS SYSTEM | GRIK5, GRIN1, GRIN3A | KDM4C 959/4885PPARA 2123/4885STING1 4206/4885 |
| US-20250255844-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS | HAO2, ACOX1, HAO1 | KDM4C 3145/4885PPARA 813/4885STING1 2942/4885 |
| US-12285402-B2 | Compositions and methods for treating pulmonary disorders | HAO2, ACOX1, HAO1 | KDM4C 3145/4885PPARA 813/4885STING1 2942/4885 |
| US-20100323995-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING NEURODEGENERATION IN ACUTE AND CHRONIC INJURIES IN THE CENTRAL NERVOUS SYSTEM | GRIK5, GRIN1, GRIN3A | KDM4C 959/4885PPARA 2123/4885STING1 4206/4885 |
| US-20070298129-A1 | Compounds and compositions for treating neuronal death or neurological dysfunction | BCL2, BAX, SMN1; SMN2 | KDM4C 3544/4885PPARA 1265/4885STING1 3945/4885 |
| US-20120040939-A1 | MEDICINAL USE OF 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE OR ITS SALT | HTR5A, HTR6, MC5R | KDM4C 2416/4885PPARA 1630/4885STING1 4235/4885 |
| US-20030097018-A1 | Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system | GRIK5, GRIN2A, GRIN2C | KDM4C 1099/4885PPARA 1754/4885STING1 4240/4885 |
| US-20070049565-A1 | Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction | BAD, MAP1LC3B, XIAP | KDM4C 4402/4885PPARA 4072/4885STING1 3607/4885 |
| US-20220249343-A1 | COSMETIC COMPOSITION INCLUDING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE, AND TOPICAL USE THEREOF | ALOX5, ALOX15, IL5 | KDM4C 1095/4885PPARA 908/4885STING1 1303/4885 |
| US-20030045575-A1 | Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system | GRIK5, GRIN2A, GRIN2C | KDM4C 1099/4885PPARA 1754/4885STING1 4240/4885 |
| US-20060128677-A1 | Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system | GRIK5, GRIN1, GRIN3A | KDM4C 959/4885PPARA 2123/4885STING1 4206/4885 |
| US-20200206172-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | PRNP, PSEN1, GRIK5 | KDM4C 2280/4885PPARA 3388/4885STING1 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.